A Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2017
At a glance
- Drugs MVA 5T4 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TRIOC
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2017 Planned number of patients changed from 96 to 97.
- 31 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 May 2019.